GOSS NASDAQ
Gossamer Bio, Inc.
1W: +8.5%
1M: -16.4%
3M: -44.2%
YTD: -96.0%
1Y: -94.5%
3Y: -79.6%
5Y: -99.2%
$9.77
+0.62 (+6.78%)
After Hours: $9.57 (-0.20, -2.00%)
Weekly Expected Move ±11.4%
$7
$9
$10
$11
$12
Credit Risk of going bust: higher than 94% of companies Debt: 41.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.93 (down 79%), Gossamer Bio, Inc. would be worth roughly what it owes.
Total debt $39.1M against a stock market value of $55.9M.
Distance to default 0.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.1M (short-term plus half of long-term), stock volatility 118.5%; Altman Z'' -86.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.93 (down 79%), Gossamer Bio, Inc. would be worth roughly what it owes.
Total debt $39.1M against a stock market value of $55.9M.
Distance to default 0.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.1M (short-term plus half of long-term), stock volatility 118.5%; Altman Z'' -86.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$55.9M
52W Range8.29-309.6
Volume250,631
Avg Volume332,266
Beta2.00
Dividend—
Analyst Ratings
Company Info
CEOFaheem Hasnain
Employees162
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-08
Websitegossamerbio.com
3115 Merryfield Row
San Diego, CA 92121
US
San Diego, CA 92121
US
858 684 1300
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Latest News
Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Target Price of $256.00
396,727 Shares of Gossamer Bio, Inc. $GOSS Acquired by Bank of America Corp DE
Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension
Squarepoint Ops LLC Decreases Holdings in Gossamer Bio, Inc. $GOSS
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Milligan Sandra | A-Award | 10,000 | $10.99 | 2026-09-23 |
| Daniel Thomas O | A-Award | 10,000 | $10.99 | 2026-09-23 |
| Ciongoli Gregory Aus | A-Award | 30,000 | $10.99 | 2026-09-23 |
| Drynan Skye | A-Award | 10,000 | $10.99 | 2026-09-23 |
| Quisel John D | A-Award | 10,000 | $10.99 | 2026-09-23 |